Visual hallucinations from the addition of riluzole to memantine and bupropion [7]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 2, 2006, Pages 218-220

  Pittenger, Christopher ^a   Naungayan, Christine ^a   Kendell, Steven F ^a   Coric, Vladimir ^a   Malison, Robert ^a   Krystal, John H ^a   Sanacora, Gerard S ^a  

^a Yale University School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMOXAPINE; CLOZAPINE; DEXAMPHETAMINE; DIAZEPAM; GABAPENTIN; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MEMANTINE; MIRTAZAPINE; OLANZAPINE; QUETIAPINE; RILUZOLE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TIAGABINE; VALPROATE SEMISODIUM; VENLAFAXINE;

ADD ON THERAPY; ADULT; ALCOHOL ABUSE; BECK DEPRESSION INVENTORY; CASE REPORT; FAMILY HISTORY; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; LETTER; MAJOR DEPRESSION; NEUROTRANSMISSION; PRIORITY JOURNAL; PSYCHOTRAUMA; SUICIDAL IDEATION; VISUAL HALLUCINATION;

ADULT; BUPROPION; DEPRESSIVE DISORDER, MAJOR; DOPAMINE UPTAKE INHIBITORS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HALLUCINATIONS; HUMANS; MEMANTINE; RILUZOLE;

EID: 33646680521     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000203228.64117.9f     Document Type: Letter

References (15)

1. Sanacora G, Rothman DL, Mason G, et al. Clinical studies implementing glutamate neurotransmission in mood disorders. Ann N Y Acad Sci. 2003;1003:292-308.
2. Krystal JH, Sanacora G, Blumberg H, et al. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 2002;7:S71-S80.
3. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351-354.
4. Hahn C-G, Gyulai L, Baldassano CF, et al. The current understanding of lamotrigine as a mood stabilizer. J Clin Psychiatry. 2004;65:791-804.
5. Zarate CA, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004;161:171-174.
6. Coric V, Milanovic S, Wasylink S, et al. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology. 2003;167:219-220.
7. Sanacora G, Kendell SF, Fenton L, et al. Riluzole augmentation for treatment-resistant depression. Am J Psychiatry. 2004;161:2132.
8. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open label trial. Biol Psychiatry. 2005;58:424-428.
9. Riederer P, Lange KW, Kornhuber J, et al. Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet. 1991;338:1022-1023.
10. Settle EC Jr. Bupropion sustained release: side effect profile. J Clin Psychiatry. 1998;59:S32-S36.
11. Howard WT, Warnock JK. Bupropion-induced psychosis.Am J Psychiatry. 1999;156:2017-2018.
12. Cancelli I, Marcon G, Balestrieri M. Factors associated with complex visual hallucinations during antidepressant treatment. Hum Psychopharmacol. 2004;19:577-584.
13. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1988;1:179-186.
14. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199-214.
15. Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A. 1996;93:9235-9240.